Your Article Summary
See Latest ArticlesTopoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer
Anti-Cancer Drugs, 07/02/09
Post S et al. - In a study to assess whether expression of topoisomerase I (Topo I) and thymidylate synthase (TS) helps predict treatment response in pts undergoing irinotecan and capecitabine-based chemoradiation, it was reported that Topo I expression in rectal tumour mucosa might serve as a predictor of response to neoadjuvant irinotecan-based chemoradiation, and might be a factor contributing to development of individualized treatment.
Methods- Pts with rectal cancer (cT3/4Nx or Tx/N+) received neoadjuvant chemoradiotherapy within clinical studies with irinotecan and capecitabine.
- Samples of normal and tumour tissues were collected before start of treatment and during surgical resection.
- Topo I and TS were measured using real-time PCR.
- 38 pts were analysed, 18 of them were responders.
- Biopsies of untreated tumour tissue of responding pts showed a significant higher expression of Topo I vs nonresponding pts.
- Normal tissue did not show this difference.
- During chemoradiation, Topo I expression in tumour tissue of responders decreased significantly.
- TS did not show any differences between responders and nonresponders before treatment, but a significant decrease in the tumour tissue of responders was noted at the end of treatment.
Related Articles
Obesity linked to specific cancers
Internet Source, 11/05/09
Relevance Score: 69%
Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women
Cancer Causes and Control, 10/28/09
Relevance Score: 69%
Childhood Cancer Survivors Experience Suicidal Thoughts Decades After Diagnosis
ScienceDaily, 10/27/09
Relevance Score: 69%
American Cancer Society Stands by Cancer Screening Guidelines
MedLinePlus, 10/23/09
Relevance Score: 69%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 69%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer
Cancer Treatment Reviews, 12/04/09
Dysregulation of Platelet-Derived Growth Factor beta-Receptor Expression by deltaNp73 in Neuroblastoma
Molecular Cancer Research, 12/04/09
Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression
Virchows Archiv, 12/04/09
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
EORTC Elderly Task Force experts opinion for the treatment of colon cancer in older patients
Cancer Treatment Reviews, 12/04/09
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
Annals of Oncology, 12/04/09
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
Annals of Oncology, 12/04/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA)
Medical Oncology, 12/04/09
Clinicopathological characteristics of primary gastric T-cell lymphoma
Histopathology, 12/04/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09